Skip to main content
    E

    Enveric Biosciences Inc (ENVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.44
    -0.08 (-4.95%)

    Market Cap: $6.78M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Enveric Biosciences Inc (ENVB) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Enveric Biosciences (ENVB) trades at 0.2x sales and 1.1x book value. Its P/B of 1.1x is above its 5-year median of 0.7x. Its forward P/E is 23.1x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E23.1x
    Price to sales0.2x
    Price to book1.1x
    PEGN/A
    FCF yield-141.5%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B1.1x0.7xN/A
    Medians of month-end values through Oct 2026: 49 months (5-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/B, its P/B ranged from 0.2x in 2022 to 10.8x in 2016.

    Year endPriceP/SP/B
    2025$3.63N/A0.9x
    2024$64.51N/AN/A
    2023$233.983.1x1.0x
    2022$374.36N/A0.2x
    2021$8,369.16N/A1.2x
    2020$13,318.67N/AN/A
    2019$20,337.97N/AN/A
    2018$39,236.08N/AN/A
    2017$697,430.40N/AN/A
    2016$1,464,603.83N/A10.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About ENVB

    What is ENVB's forward P/E ratio?

    Enveric Biosciences has a forward P/E ratio of 23.1x.

    What is ENVB's price to sales ratio?

    Enveric Biosciences has a price to sales ratio of 0.2x.